Evidence map›Paper›PMID 39870769›Full record

ArticleScientific reports2025

Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301).

Tomonori Araki, Yuki Sonoda, Mototsugu Shimokawa, Taiga Otsuka, Kohei Hayashi, Takuya Honda, Kazuhiko Nakao, Taro Shibuki, Junichi Nakazawa, Shiho Arima and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Tomonori ArakiDepartment of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Yuki SonodaDepartment of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Mototsugu ShimokawaClinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan.
Taiga OtsukaDepartment of Internal Medicine, Minato Medical Clinic, Fukuoka, Japan.
Kohei HayashiDepartment of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Takuya HondaDepartment of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Kazuhiko NakaoDepartment of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Taro ShibukiDepartment for the Promotion of Drug and Diagnostic Development, Division of Drug and Diagnostic Development Promotion, Translational Research Support Office, National Cancer Center Hospital East, Chiba, Japan.
Junichi NakazawaDepartment of Medical Oncology, Kagoshima City Hospital, Kagoshima, Japan.
Shiho ArimaDigestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Keisuke MiwaMultidisciplinary Treatment Cancer Center, Kurume University Hospital, Fukuoka, Japan.
Yoshinobu OkabeDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.
Futa KogaDepartment of Hepatobiliary and Pancreatology, Saga Medical Center Koseikan, Saga, Japan.
Yujiro UedaDepartment of Hematology and Oncology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan.
Yoshihito KubotsuDepartment of Internal Medicine, Karatsu Red Cross Hospital, Saga, Japan.
Hozumi ShimokawaDepartment of Hematology Oncology, Community Healthcare Organization Kyushu Hospital, Fukuoka, Japan.
Shigeyuki TakeshitaDepartment of Gastroenterology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Azusa KomoriDepartment of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.
Kazuo NishikawaDepartment of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.
Satoshi OtsuDepartment of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.
Ayumu HosokawaDepartment of Clinical Oncology, University of Miyazaki Hospital, Miyazaki, Japan.
Hisanobu OdaDivision of Integrative Medical Oncology, Saiseikai Kumamoto Hospital, Kumamoto, Japan.
Tatsunori SakaiDepartment of Medical Oncology, NHO Kumamoto Medical Center, Kumamoto, Japan.
Shuji AritaDepartment of Chemotherapy, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan.
Machiko KawahiraDepartment of Gastroenterology, Kagoshima Kouseiren Hospital, Kagoshima, Japan.
Hiroki TaguchiDepartment of Gastroenterology, Izumi General Medical Center, Kagoshima, Japan.
Kengo TsuneyoshiDepartment of Gastroenterology, Izumi General Medical Center, Kagoshima, Japan.
Yasunori KawaguchiDepartment of Gastroenterology, Asakura Medical Association Hospital, Fukuoka, Japan.
Toshihiro FujitaDepartment of Gastroenterology, Saiseikai Sendai Hospital, Kagoshima, Japan.
Takahiro SakaeDepartment of Gastroenterology, Saiseikai Sendai Hospital, Kagoshima, Japan.
Tsuyoshi ShirakawaResearcher of Clinical Hematology Oncology Treatment Study Group, 1-14-6 Muromi-gaoka, Nishi-ku, Fukuoka-shi, Fukuoka, 819-0030, Japan. twriver1979@gmail.com.ORCID 0000-0002-9317-8216
Toshihiko MizutaDepartment of Internal Medicine, Fujikawa Hospital, Saga, Japan.
Kenji MitsugiDepartment of Medical Oncology, Sasebo Kyosai Hospital, Sasebo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The relationship between nanoliposomal irinotecan/fluorouracil/leucovorin (NFF) treatment outcomes and neutropenia in patients with pancreatic cancer has not been thoroughly examined. Thus, we conducted a retrospective analysis of data from patients with pancreatic cancer who were treated with NFF to investigate this relationship. Neutropenia was assessed according to the Common Terminology Criteria for Adverse Events across three cutoffs: A (grade 0 versus grade 1-4), B (grades 0-1 versus 2-4), and C (grades 0-2 versus 3-4). The primary endpoint was overall survival (OS), and the secondary endpoints were overall response rate, progression-free survival (PFS), and relative dose intensity. Of the 161 patients, 93, 8, 22, 30, and 8 patients had neutropenia of grades 0, 1, 2, 3, and 4, respectively. The overall response rates differed significantly at cutoff C (p = 0.02), with the odds ratio for cutoff C being the highest, followed by cutoffs B and A. Significant differences in OS were observed at cutoffs A (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.44-0.94; p = 0.02) and B (HR, 0.63; 95% CI, 0.43-0.92, p = 0.02). Similarly, PFS showed significant differences at cutoffs A and B (p < 0.01). NFF-induced neutropenia can be a useful prognostic factor for patients with pancreatic cancer.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsFluorouracilIrinotecanLeucovorinNeutropeniaPancreatic NeoplasmsAdultAgedAged, 80 and overFemaleHumansLiposomesMaleMiddle AgedRetrospective StudiesTreatment OutcomeFluorouracilIrinotecanLeucovorinLiposomes

Identifiers

PMID39870769
PMCPMC11772893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.